微生物群
肠道微生物群
药品
肠道菌群
生物
抗生素
人体微生物群
医学
计算生物学
生物信息学
免疫学
药理学
微生物学
作者
Rinse K. Weersma,Alexandra Zhernakova,Jingyuan Fu
出处
期刊:Gut
[BMJ]
日期:2020-05-14
卷期号:69 (8): 1510-1519
被引量:559
标识
DOI:10.1136/gutjnl-2019-320204
摘要
The human gut microbiome is a complex ecosystem that can mediate the interaction of the human host with their environment. The interaction between gut microbes and commonly used non-antibiotic drugs is complex and bidirectional: gut microbiome composition can be influenced by drugs, but, vice versa, the gut microbiome can also influence an individual’s response to a drug by enzymatically transforming the drug’s structure and altering its bioavailability, bioactivity or toxicity (pharmacomicrobiomics). The gut microbiome can also indirectly impact an individual’s response to immunotherapy in cancer treatment. In this review we discuss the bidirectional interactions between microbes and drugs, describe the changes in gut microbiota induced by commonly used non-antibiotic drugs, and their potential clinical consequences and summarise how the microbiome impacts drug effectiveness and its role in immunotherapy. Understanding how the microbiome metabolises drugs and reduces treatment efficacy will unlock the possibility of modulating the gut microbiome to improve treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI